Physician

A PROVEN
SAFETY PROFILE

TROGARZO® is generally well tolerated, with a low incidence of adverse reactions.

  • Overall, most (90%) adverse reactions reported were mild or moderate in severity.
  • Only 2 patients experienced severe adverse reactions (1 case of severe rash, 1 case of IRIS).
ADVERSE REACTIONS SEEN IN CLINICAL TRIAL EXPERIENCE IN >5% OF PATIENTS RECEIVING TROGARZO (+ OPTIMIZED background regimen).
  • Adverse Reaction
  • Diarrhea
  • Dizziness
  • Nausea
  • Rash*
  • Incidence (N=40)
  • 8%
  • 8%
  • 5%
  • 5%

* Includes pooled terms “rash”, “rash erythematous”, “rash generalized”, “rash macular”, “rash maculopapular”, and “rash papular”.

Doctor

A NOVEL MOA IS PART OF A FULLY ACTIVE REGIMEN TO MAKE UNDETECTABLE A POSSIBILITY AGAIN2

TROGARZO® IS INCLUDED IN THE DHHS GUIDELINES FOR MANAGING TREATMENT EXPERIENCED HIV-1 PATIENTS

2: Adapted from DHHS Guidelines: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.

WHAT THE DHHS GUIDELINES RECOMMEND FOR TREATMENT EXPERIENCED HIV PATIENTS
HIV Virus

DEFINE FAILURE: HIV RNA ≥ 200 copies/mL

Persistent HIV RNA ≥ 200 copies/mL is considered virologic failure, and is associated with accumulation of drug-resistance mutations.

Document Modification

BE PROACTIVE: MODIFY AS SOON AS POSSIBLE

When resistance mutations compromise a regimen, it should be modified as soon as possible to avoid progressive accumulation of resistance mutations.

Virologic responses to new regimens are greater in patients with lower HIV RNA levels and/or higher CD4 cell counts.

Thus, a change is best done before viremia worsens or CD4 count declines.

Active Regimen

CHOOSE A FULLY ACTIVE REGIMEN

A new regimen should include at least two, and preferably three, fully active agents. A fully active agent is one that is expected to have uncompromised activity on the basis of the patient’s ART history and his or her current and past drug-resistance test results.

Bottle

CONSIDER A NEWER MOA

The availability of newer ART, including those with new mechanisms of action, makes it possible to suppress HIV RNA to <50 copies/mL in most patients.